{"organizations": [], "uuid": "433d22c145a4dd3eb4b05ee74d3c83a53a79a640", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-casi-pharmaceuticals-enters-into-a/brief-casi-pharmaceuticals-enters-into-a-common-stock-sales-agreement-with-h-c-wainwright-co-idUSFWN1QD1HM", "country": "US", "domain_rank": 408, "title": "BRIEF-Casi Pharmaceuticals Enters Into A Common Stock Sales Agreement With H.C. Wainwright & Co", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-24T00:36:00.000+02:00", "replies_count": 0, "uuid": "433d22c145a4dd3eb4b05ee74d3c83a53a79a640"}, "author": "", "url": "https://www.reuters.com/article/brief-casi-pharmaceuticals-enters-into-a/brief-casi-pharmaceuticals-enters-into-a-common-stock-sales-agreement-with-h-c-wainwright-co-idUSFWN1QD1HM", "ord_in_thread": 0, "title": "BRIEF-Casi Pharmaceuticals Enters Into A Common Stock Sales Agreement With H.C. Wainwright & Co", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "h.c. wainwright & co", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "h.c. wainwright & co reuters staff", "sentiment": "none"}, {"name": "casi pharmaceuticals inc", "sentiment": "none"}, {"name": "h.c. wainwright & co llc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 23 (Reuters) - Casi Pharmaceuticals Inc:\n* CASI PHARMACEUTICALS INC SAYS ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO LLC - SEC FILING\n* CASI PHARMACEUTICALS - AS PER STOCK SALES AGREEMENT, CO MAY SELL FROM TIME TO TIME SHARES OF CO'S STOCK THROUGH HCW WITH TOTAL SALES PRICE UP TO $25 MILLION Source text: ( bit.ly/2ENog5J ) Further company coverage:\n ", "external_links": [], "published": "2018-02-24T00:36:00.000+02:00", "crawled": "2018-02-24T00:55:05.005+02:00", "highlightTitle": ""}